Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5035 participants.
Also called NCT02867813
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,035 participants
- Sponsor
- Registry
-
NCT02867813 -
2015-004780-36
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Poland, Russia, Slovakia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02867813. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-02 (actual); primary completion 2022-03-21 (actual). Results posted on 2023-02-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
- Acronym
- FOURIER OLE
- Condition
- Dyslipidemia
- Intervention (Biological)
- Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02867813- Content hash
e16a7d116caaafb3843088282e723902973575ad7dd7ab24171c85a791800e95